Tag: Byetta

According to Drugs.com, Bydureon BCise is an extended-release formulation of exenatide that is injected once weekly for the treatment of Type 2 diabetes. This definitively answers the question, **Is Bydureon long acting or short acting?** by confirming its long-acting nature. Its long-acting profile is what differentiates it from its short-acting counterpart, Byetta, which contains the same active ingredient.

In 2021, the brand-name Bydureon pen was discontinued, leading to questions about its successor and generic options. The generic name for Bydureon is **exenatide extended-release**, which is a long-acting form of the active ingredient exenatide. This medication belongs to a class of drugs known as GLP-1 receptor agonists and is used to manage type 2 diabetes by controlling blood sugar levels.

Over 38 million Americans have diabetes, with Type 2 being the most common form. For many managing this condition, understanding the differences between prescription options is crucial, especially when deciding which is better, Byetta or Bydureon.

Byetta, with the active ingredient exenatide, was the first GLP-1 receptor agonist to receive FDA approval for type 2 diabetes in 2005. It is used alongside diet and exercise to help improve glycemic control in adults who have been unable to manage their blood sugar with other therapies.